• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

希腊散发型髓样甲状腺癌中 exon 8 G533C 突变的高发生率。

High prevalence of exon 8 G533C mutation in apparently sporadic medullary thyroid carcinoma in Greece.

机构信息

1st Endocrine Section and Diabetes Center, Alexandra Hospital, Athens, Greece.

出版信息

Clin Endocrinol (Oxf). 2012 Dec;77(6):857-62. doi: 10.1111/j.1365-2265.2012.04462.x.

DOI:10.1111/j.1365-2265.2012.04462.x
PMID:22676047
Abstract

OBJECTIVE

Genetic screening for ret mutation has become routine practice in the evaluation of medullary thyroid carcinoma (MTC). Approximately 25% of these tumours are familial, and they occur as components of the multiple endocrine neoplasia type 2 syndromes (MEN 2A and 2B) or familial MTC. In familial cases, the majority of mutations are found in exons 10, 11, 13, 14 or 15 of the ret gene. A rare mutation involving exon 8 (G533C) has recently been reported in familial cases of MTC in Brazil and Greece; some of these cases were originally thought to be sporadic. The aim of this study was to re-evaluate a series of sporadic cases of MTC, with negative family history, and screen them for germline mutations in exon 8.

DESIGN AND PATIENTS

Genomic DNA was extracted from peripheral lymphocytes in 129 unrelated individuals who had previously been characterized as 'sporadic' based on the negative family history and negative screening for ret gene mutations. Samples were analysed in Applied Biosystems 7500 real-time PCR and confirmed by sequencing.

MEASUREMENTS AND RESULTS

The G533C exon 8 mutation was identified in 10 of 129 patients with sporadic MTC. Asymptomatic gene carriers were subsequently identified in other family members.

CONCLUSION

In our study, we found that 7·75% patients with apparently sporadic MTC do carry G533C mutation involving exon 8 of ret. We feel that there is now a need to include exon 8 mutation screening in all patients diagnosed as sporadic MTC, in Greece.

摘要

目的

在对甲状腺髓样癌(MTC)的评估中,RET 基因突变的遗传筛查已成为常规操作。这些肿瘤中约有 25%为家族性的,它们作为多发性内分泌肿瘤 2 型综合征(MEN 2A 和 2B)或家族性 MTC 的组成部分而发生。在家族性病例中,大多数突变发生在 RET 基因的外显子 10、11、13、14 或 15 中。最近在巴西和希腊的家族性 MTC 病例中报道了一种罕见的涉及外显子 8(G533C)的突变;其中一些病例最初被认为是散发性的。本研究的目的是重新评估一系列具有阴性家族史的散发性 MTC 病例,并对其外显子 8 中的种系突变进行筛查。

设计和患者

从 129 名先前根据阴性家族史和 RET 基因突变筛查结果被归类为“散发性”的无亲缘关系个体的外周淋巴细胞中提取基因组 DNA。应用生物系统 7500 实时 PCR 对样本进行分析,并通过测序进行确认。

测量和结果

在 129 例散发性 MTC 患者中发现了 10 例存在外显子 8 的 G533C 突变。随后在其他家族成员中发现了无症状的基因携带者。

结论

在我们的研究中,我们发现,在我们诊断为散发性 MTC 的患者中,有 7.75%的患者确实携带涉及 RET 外显子 8 的 G533C 突变。我们认为,现在有必要在希腊所有被诊断为散发性 MTC 的患者中纳入外显子 8 突变筛查。

相似文献

1
High prevalence of exon 8 G533C mutation in apparently sporadic medullary thyroid carcinoma in Greece.希腊散发型髓样甲状腺癌中 exon 8 G533C 突变的高发生率。
Clin Endocrinol (Oxf). 2012 Dec;77(6):857-62. doi: 10.1111/j.1365-2265.2012.04462.x.
2
RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.甲状腺髓样癌患者及其亲属的RET基因筛查:一个中心807例个体的经验
J Clin Endocrinol Metab. 2007 Dec;92(12):4725-9. doi: 10.1210/jc.2007-1005. Epub 2007 Sep 25.
3
Multiple endocrine neoplasia type 2A due to an exon 8 (G533C) mutation in a large North American kindred.2A 型多发性内分泌肿瘤源于一个大型北美的家族性系谱中第 8 外显子(G533C)的突变。
Thyroid. 2013 Dec;23(12):1547-52. doi: 10.1089/thy.2012.0599. Epub 2013 Jul 25.
4
Germline RET mutations in exons 10 and 11: an Iranian survey of 57 medullary thyroid carcinoma cases.第10和11外显子中的种系RET突变:一项针对57例甲状腺髓样癌病例的伊朗调查。
Med J Malaysia. 2006 Dec;61(5):564-9.
5
Genetic screening of patients with medullary thyroid cancer in a referral center in Greece during the past two decades.在过去的二十年中,对希腊一家转诊中心的甲状腺髓样癌患者进行了基因筛查。
Eur J Endocrinol. 2015 Apr;172(4):501-9. doi: 10.1530/EJE-14-0817. Epub 2015 Jan 26.
6
Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.在源自葡萄牙中部地区的2型多发性内分泌腺瘤病家族及散发性甲状腺髓样癌病例中,RET原癌基因出现Cys611Tyr突变及一种新型的Arg886Trp替代。
Clin Endocrinol (Oxf). 2006 Jun;64(6):659-66. doi: 10.1111/j.1365-2265.2006.02524.x.
7
Molecular analysis of the RET proto-oncogene key exons in patients with medullary thyroid carcinoma: a comprehensive study of the Iranian population.对甲状腺髓样癌患者 RET 原癌基因关键外显子的分子分析:对伊朗人群的综合研究。
Thyroid. 2011 Apr;21(4):373-82. doi: 10.1089/thy.2010.0267.
8
RET mutation status in medullary thyroid cancer(MTC) patients and the significance of genetic screening for mutations in their immediate relatives--a preliminary report.甲状腺髓样癌(MTC)患者的RET突变状态及其直系亲属基因突变筛查的意义——初步报告
Indian J Pathol Microbiol. 2005 Apr;48(2):161-5.
9
Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.散发性甲状腺髓样癌患者RET原癌基因种系突变频率较低。
Clin Endocrinol (Oxf). 1995 Jul;43(1):123-7. doi: 10.1111/j.1365-2265.1995.tb01903.x.
10
The relationship of cytomorphology of medullary thyroid carcinomas between family members with the same RET proto-oncogene mutation.具有相同RET原癌基因突变的甲状腺髓样癌家族成员之间的细胞形态学关系。
Acta Cytol. 2011;55(6):556-62. doi: 10.1159/000333246. Epub 2011 Dec 9.

引用本文的文献

1
RET Proto-Oncogene Variants in Patients with Medullary Thyroid Carcinoma from the Mediterranean Basin: A Brief Report.地中海地区甲状腺髓样癌患者的RET原癌基因变异:简要报告
Life (Basel). 2023 Jun 6;13(6):1332. doi: 10.3390/life13061332.
2
Medullary Thyroid Cancer: Updates and Challenges.甲状腺髓样癌:更新与挑战。
Endocr Rev. 2023 Sep 15;44(5):934-946. doi: 10.1210/endrev/bnad013.
3
Crude annual incidence rate of medullary thyroid cancer and RET mutation frequency.甲状腺髓样癌的粗年发病率和 RET 突变频率。
Croat Med J. 2021 Apr 30;62(2):110-119. doi: 10.3325/cmj.2021.62.110.
4
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations.RET 基因遗传筛查在遗传性 MTC 中的 25 年经验:种系 RET 突变的流行率更新。
Genes (Basel). 2019 Sep 10;10(9):698. doi: 10.3390/genes10090698.
5
Genotype and phenotype landscape of MEN2 in 554 medullary thyroid cancer patients: the BrasMEN study.554例甲状腺髓样癌患者中MEN2的基因型和表型图谱:巴西MEN2研究
Endocr Connect. 2019 Mar 1;8(3):289-298. doi: 10.1530/EC-18-0506.
6
Familial MTC with exon 8 Gly533Cys mutation: origin and prevalence of second malignancy.伴有第8外显子Gly533Cys突变的家族性甲状腺髓样癌:第二原发恶性肿瘤的起源与患病率
Endocr Connect. 2017 Nov;6(8):676-684. doi: 10.1530/EC-17-0147. Epub 2017 Sep 26.
7
Management of hereditary medullary thyroid carcinoma.遗传性甲状腺髓样癌的管理
Endocrine. 2016 Jul;53(1):7-17. doi: 10.1007/s12020-016-0873-1. Epub 2016 Feb 2.
8
2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer.2012 年欧洲甲状腺协会关于甲状腺髓样癌基因检测及其临床后果的指南。
Eur Thyroid J. 2013 Jan;1(4):216-31. doi: 10.1159/000346174. Epub 2012 Dec 19.
9
Metachronous appearance of second malignancies in medullary thyroid carcinoma (MTC) patients: a diagnostic challenge and brief review of the literature.甲状腺髓样癌(MTC)患者第二恶性肿瘤的异时性表现:诊断挑战及文献简述。
Endocrine. 2013 Dec;44(3):610-5. doi: 10.1007/s12020-013-9961-7. Epub 2013 Apr 23.
10
The optimal range of RET mutations to be tested: European comments to the guidelines of the American Thyroid Association.需检测的RET突变的最佳范围:欧洲对美国甲状腺协会指南的评论
Thyroid Res. 2013 Mar 14;6 Suppl 1(Suppl 1):S8. doi: 10.1186/1756-6614-6-S1-S8.